Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4QZ3O
|
|||
| Drug Name |
SEA-BCMA
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Phase 1 | [1] | |
| Company |
Seagen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell maturation protein (TNFRSF17) | Target Info | . | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03582033) A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.